Andre Picard, commenting on the recent report on Canada’s Personal Genome Project, suggests that genomics has entered its frustrating adolescent phase. This study found that our genome “is a lot more messy and unpredictable than anyone could have imagined. Like a typical teenager.”
Scientists leading Canada’s Personal Genome Project say they have taken the deepest dive possible into human DNA, conducting the most thorough analysis that current computing allows on the whole genome sequences of 56 Canadians. Their investigation shows how much we still have to learn.
Ontario Genomics is delighted with the recent news that Nicoya Lifesciences (Nicoya) has raised $2 million in financing from a syndicate of investors in the Toronto-Waterloo corridor, led by Ripple Ventures. Ontario Genomics, through its Pre-commercialization Business Development Fund, previously invested in Nicoya to help advance Nicoya’s flagship product, OpenSPR – a label-free, real time molecule sensor. It has many applications, including enabling drug discovery. Congratulations to the team at Nicoya!
A national consortium of industry and academic collaborators have launched the Canadian Genomics Cloud, an integrated software platform to manage, analyze and share genome sequence and clinical data. As detailed in an accompanying white paper, this public cloud computing platform will give every scientist in the country unfettered access to award-winning technology empowering precision medicine and other applications in genomics research.
To commemorate the 150th Birthday of Canada in 2017 and to lay the foundation of Canadian excellence in research for the next 150 years, Canada’s Genomics Enterprise (CGEn) and its partners are embarking upon the Canada 150 Sequencing Project (CanSeq150). The aim is to sequence 150 new genomes to support sequence-based genomics research in Canada by enabling future…
Fabry disease is a rare genetic disease caused by a deficiency in the enzyme alpha-galactosidase A (a-Gal A) that causes a buildup of a specific type of fat in the body. Galafold™ (migalastat), a new oral drug to treat some patients with Fabry disease, has just received a positive recommendation by the CADTH Common Drug Review for reimbursement and listing with provincial drug formularies.
Pionyr Immunotherapeutics, a biotech startup, raises $62 million in series B investment round and is now planning to take its anti-cancer therapy to clinical trials.
It has been 15 years since the publication of the complete human genome. During that time, many organisms have been sequenced from crops and animals to simple organisms like bacteria. The Earth BioGenome Project (EBP) has proposed an audacious goal: to sequence, within a decade, the genomes of all 1.5m known species of plants, animals and fungi. The $500M project could create an enormous data resource that could help answer fundamental question, discover new drugs and materials, and more.
A new nanopore technology for direct sequencing of long strands of DNA has resulted in the most complete human genome ever assembled with a single technology, scientists have revealed. The research, published today in Nature Biotechnology, included scientists from the University of British Columbia and the Ontario Institute for Cancer Research (Jared Simpson, pictured above). Using an emerging technology – a pocket sized, portable DNA sequencer – the scientists sequenced a complete human genome, in fragments hundreds of times larger than usual, enabling new biological insights.
A proud day for all Canadians with the announcement of $255 million to support genomic innovations and advance precision health. Congratulations to all of the award-winning teams across Ontario and Canada.